GSK plc (GSK)

What is GSK and what does it do?

GSK plc is a pharmaceutical and healthcare company headquartered in London. The name is shorthand for GlaxoSmithKline, formed in 2000 from the merger of two British pharmaceutical firms, Glaxo Wellcome and SmithKline Beecham, both of which trace their roots back to the 19th century. The modern GSK makes prescription drugs (primarily vaccines and specialty medicines for respiratory disease, oncology, and immunology), consumer health products (over-the-counter pain relievers, cold remedies, dental care, and nutritional supplements), and has a growing pipeline in areas like genetic medicine and autoimmune disease. The company operates at scale across multiple geographies and therapeutic areas, making it one of the world’s largest pharmaceutical companies by revenue and market capitalization, though not the most profitable on a earnings-per-share basis.

How did GSK get here?

Glaxo’s roots run to 1873 and the Glaxo company, which started in New Zealand and moved to Britain. SmithKline Beecham traces back to the 1830s and Philadelphia. Both companies grew through the 20th century as pharmaceutical science advanced, building large sales forces and research facilities. Glaxo in particular became famous for discovering and marketing the inhaled asthma drug Ventolin (albuterol), which was a blockbuster and a template for the company’s respiratory business. The 1989 merger between Glaxo Wellcome and SmithKline Beecham created a behemoth, and for the next 15 years GSK was a dominant name in global pharma, driven by a string of blockbuster drugs including the respiratory drugs Avandia and Advair, the HIV medicine Combivir, and the vaccine Cervarix for cervical cancer.

That period of strength began to crack in the late 2000s and early 2010s. Several major drugs faced patent cliffs—the moment when exclusive patents expire and generic competitors flood the market—and GSK struggled to backfill them with new approvals. At the same time, the company faced a series of regulatory and reputational challenges around drug pricing, off-label marketing, and dividend sustainability. By 2015, new leadership began a deliberate restructuring, dividing the company into a sharper prescription-drug unit and a spun-out consumer-health company (now called Haleon). The intent was to focus GSK on specialty pharmaceuticals and vaccines, where margins are higher and the competitive position is stronger.

What makes GSK’s business distinctive?

GSK is unusual among large pharmaceutical companies in how deeply embedded it is in public health. Vaccines are the centerpiece. The company’s vaccine portfolio includes Shingrix (for shingles), Bexsero (for meningococcal disease), Arexvy (for recombinant zoster vaccination), and a slate of combination pediatric vaccines and immunizations. Vaccines are not typically blockbusters in pure revenue terms, but they are high-margin, recurring, and essential to global health security. Every child who gets vaccinated is a GSK customer, potentially for multiple years and across multiple products. Governments also buy vaccines in bulk, creating a stable, predictable revenue stream that looks unlike the hit-driven model of cancer or rare-disease drugs. GSK has invested heavily in vaccine manufacturing and distribution infrastructure, making it difficult for competitors to match scale.

The second pillar is specialty pharmaceuticals, primarily respiratory and immuno-inflammatory drugs. The respiratory franchise inherited from Glaxo—drugs like Ellipta, which deliver steroids and long-acting bronchodilators to asthma and chronic obstructive pulmonary disease (COPD) patients—still generates substantial revenue. The immuno-inflammatory pipeline includes treatments for asthma with immune-system involvement, atopic dermatitis, and other conditions where immune dysregulation is central. These are not blockbusters, but they are valuable franchises tied to large patient populations and recurring treatment regimens.

GSK has also made a strategic bet on genetic medicine and rare diseases through significant acquisitions and internal research, attempting to gain exposure to high-margin treatments for small patient populations where pricing power is greater. This is a long-term play, and success is uncertain.

What makes GSK competitive?

The company’s advantages cluster around distribution and regulatory relationships. GSK has a direct sales force in most major markets, allowing it to detail physicians and reach patients quickly once a drug is approved. Its vaccine business gives it relationships with health ministries and government procurement agencies globally, built over decades. The regulatory expertise the company has accumulated—understanding how to run trials, navigate approvals, and manage post-market surveillance—is harder to replicate than simple scientific capability. And the company has brands. Theraflu, Sensodyne, Nicorette, and Panadol are household names with real equity in consumer markets. The consumer health spin-out in 2022 (Haleon) technically owns those now, but GSK maintains relationships and can co-market.

What are the real risks?

Pharmaceutical companies live under constant threat of patent expiration. A blockbuster drug loses exclusivity and generics capture 80% of the market within months. GSK faces this cliff pressure repeatedly, and the company’s ability to replace expiring drugs with new approvals drives its stock price. R&D productivity in pharma is notoriously uncertain; most drugs in development fail to get approved or turn out to be less commercially important than hoped. GSK’s pipeline must consistently deliver approvals that generate billions in peak sales to offset declines in older franchises. This is an inherently risky business, and few companies execute this transition perfectly.

Pricing pressure is another constant threat. Governments and healthcare payers everywhere are pushing back against high drug prices, and GSK has faced specific scrutiny over hepatitis-C drugs, oncology-drug pricing, and the margin structure of vaccines. Regulatory changes in any major market—the United States, Europe, or Japan—could significantly pressure the business.

The separation of the consumer-health business (Haleon) in 2022 also means GSK is no longer diversified across prescription and OTC products. It is now a pure-play pharma company, with all the corresponding cyclicality.

How to research GSK as an investment

Start with the annual 10-K (SEC CIK 0001131399), which breaks revenue by therapeutic area and geography and details the pipeline. The quarterly earnings calls reveal how sales are trending in mature franchises and how physicians and payers are responding to new drugs. Watch the gross margins—pharma companies jealously guard high margins, and erosion usually signals either competitive pressure or an unfavorable product mix. The pipeline disclosure is crucial; GSK will typically lay out key upcoming approvals and the estimated peak-sales potential of candidates in Phase II and Phase III development. Any commentary on patent cliffs and genericization timelines for major drugs is essential context. Also track the company’s capital allocation—how much is being invested in R&D relative to peers, and what acquisitions are being made to shore up the pipeline. Vaccine revenues and government procurement trends are worth monitoring separately, as they have different dynamics than oncology or respiratory drugs. As always, nothing here is a recommendation; pharmaceutical stocks are volatile, inherently risky, and sensitive to clinical trial results, regulatory decisions, and reimbursement changes that can materialize suddenly.